148 related articles for article (PubMed ID: 23280413)
1. Pharmacophore modeling and virtual screening studies to design potential COMT inhibitors as new leads.
Jatana N; Sharma A; Latha N
J Mol Graph Model; 2013 Feb; 39():145-64. PubMed ID: 23280413
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore-based virtual screening of catechol-o-methyltransferase (COMT) inhibitors to combat Alzheimer's disease.
Patel CN; Georrge JJ; Modi KM; Narechania MB; Patel DP; Gonzalez FJ; Pandya HA
J Biomol Struct Dyn; 2018 Nov; 36(15):3938-3957. PubMed ID: 29281938
[TBL] [Abstract][Full Text] [Related]
3. The 108M polymorph of human catechol O-methyltransferase is prone to deformation at physiological temperatures.
Rutherford K; Bennion BJ; Parson WW; Daggett V
Biochemistry; 2006 Feb; 45(7):2178-88. PubMed ID: 16475806
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of human 108V and 108M catechol O-methyltransferase.
Rutherford K; Le Trong I; Stenkamp RE; Parson WW
J Mol Biol; 2008 Jun; 380(1):120-30. PubMed ID: 18486144
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel inhibitors against Mycobacterium tuberculosis L-alanine dehydrogenase (MTB-AlaDH) through structure-based virtual screening.
Saxena S; Devi PB; Soni V; Yogeeswari P; Sriram D
J Mol Graph Model; 2014 Feb; 47():37-43. PubMed ID: 24316937
[TBL] [Abstract][Full Text] [Related]
6. Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors.
Ellermann M; Paulini R; Jakob-Roetne R; Lerner C; Borroni E; Roth D; Ehler A; Schweizer WB; Schlatter D; Rudolph MG; Diederich F
Chemistry; 2011 May; 17(23):6369-81. PubMed ID: 21538606
[TBL] [Abstract][Full Text] [Related]
7. Identification of COMT and ErmC inhibitors by using a microplate assay in combination with library focusing by virtual screening.
Kreander K; Kurkela M; Siiskonen A; Vuorela P; Tammela P
Pharmazie; 2006 Mar; 61(3):247-8. PubMed ID: 16599271
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore filtering and 3D-QSAR in the discovery of new JAK2 inhibitors.
Dhanachandra Singh Kh; Karthikeyan M; Kirubakaran P; Nagamani S
J Mol Graph Model; 2011 Sep; 30():186-97. PubMed ID: 21831680
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of ortho- and meta-nitrated inhibitors of catechol-O-methyltransferase: interactions with the active site and regioselectivity of O-methylation.
Palma PN; Rodrigues ML; Archer M; Bonifácio MJ; Loureiro AI; Learmonth DA; Carrondo MA; Soares-da-Silva P
Mol Pharmacol; 2006 Jul; 70(1):143-53. PubMed ID: 16618795
[TBL] [Abstract][Full Text] [Related]
11. Crystal structures of rat catechol-O-methyltransferase complexed with coumarine-based inhibitor.
Tsuji E; Okazaki K; Takeda K
Biochem Biophys Res Commun; 2009 Jan; 378(3):494-7. PubMed ID: 19056347
[TBL] [Abstract][Full Text] [Related]
12. The V108M mutation decreases the structural stability of catechol O-methyltransferase.
Rutherford K; Alphandéry E; McMillan A; Daggett V; Parson WW
Biochim Biophys Acta; 2008; 1784(7-8):1098-105. PubMed ID: 18474266
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore mapping and in silico screening to identify new potent leads for A(2A) adenosine receptor as antagonists.
Mustyala KK; Chitturi AR; Naikal James PS; Vuruputuri U
J Recept Signal Transduct Res; 2012 Apr; 32(2):102-13. PubMed ID: 22384789
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors.
Wu D; Jin F; Lu W; Zhu J; Li C; Wang W; Tang Y; Jiang H; Huang J; Liu G; Li J
Chem Biol Drug Des; 2012 Jun; 79(6):897-906. PubMed ID: 22381062
[TBL] [Abstract][Full Text] [Related]
15. Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models.
Boppana K; Dubey PK; Jagarlapudi SA; Vadivelan S; Rambabu G
Eur J Med Chem; 2009 Sep; 44(9):3584-90. PubMed ID: 19321235
[TBL] [Abstract][Full Text] [Related]
16. Identification of potent virtual leads to design novel indoleamine 2,3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies.
John S; Thangapandian S; Sakkiah S; Lee KW
Eur J Med Chem; 2010 Sep; 45(9):4004-12. PubMed ID: 20580138
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads.
Vadivelan S; Sinha BN; Rambabu G; Boppana K; Jagarlapudi SA
J Mol Graph Model; 2008 Feb; 26(6):935-46. PubMed ID: 17707666
[TBL] [Abstract][Full Text] [Related]
18. Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening.
Dessalew N; Bharatam PV
Chem Biol Drug Des; 2006 Sep; 68(3):154-65. PubMed ID: 17062013
[TBL] [Abstract][Full Text] [Related]
19. Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders.
Ma Z; Liu H; Wu B
Br J Clin Pharmacol; 2014 Mar; 77(3):410-20. PubMed ID: 23713800
[TBL] [Abstract][Full Text] [Related]
20. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
Kaur M; Silakari O
J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
